Abstract: The present disclosure relates to a nitric oxide-sensitive hydrogel. The hydrogel is formed through in-situ hybridization in a target site by means of a click chemical reaction and is prepared using a nitric oxide-sensitive crosslinker. The hydrogel can effectively collect and scavenge nitric oxide overexpressed in the target site, and a drug loaded in the hydrogel can be locally and sensitively released to a target site to be treated. Therefore, the hydrogel can be effectively used to prevent and treat inflammatory disease caused by the overexpression of nitric oxide.

Abstract: The present disclosure relates to an apparatus and method for gene amplification. The apparatus for gene amplification may include: an upper main body comprising a first inlet to receive a sealing solution, a second inlet to receive a sample solution, and an upper passage that allows the sample solution and the sealing solution to move by capillary action; a lower main body disposed to oppose the upper main body, and having a lower passage through which the sealing solution moves by capillary action after being injected from the first inlet of the upper main body; a gene amplification chip configured to be inserted between the upper main body and the lower main body; and a porous medium configured to be inserted between the upper main body and the lower main body.

Abstract: An electronic device includes a connector connected to a cable external to the electronic device and including a plurality of pins; a first water detection circuit connected to at least one first pin of the plurality of pins and generating a first detection result by detecting whether there is water in the connector based on resistance of the at least one first pin; and a second water detection circuit connected to at least one second pin of the plurality of pins, entering a water detection mode when the first detection result indicates the presence of water, and detecting whether there is water in the connector based on resistance of the at least one second pin.

Abstract: The present disclosure relates to a magnetic resonance imaging (MRI) contrast agent containing a gadolinium complex, and more specically, to a DO3A-tranexamic acid compound having a structure of a chemical formula 1, or an ester compound thereof, and gadolinium complexes thereof. The DO3A-tranexamic acid compound or the ester compound thereof may be used to prepare gadolinium complexes. The gadolinium complexes exhibit thermodynamic and kinetic stabilities, and show the relaxation rate equal to that of the clinical contrast agent which is currently commercially available. Therefore, the gadolinium complexes can be widely used as an MRI contrast agent.

Abstract: An electronic device includes a connector connected to a cable external to the electronic device and including a plurality of pins; a first water detection circuit connected to at least one first pin of the plurality of pins and generating a first detection result by detecting whether there is water in the connector based on resistance of the at least one first pin; and a second water detection circuit connected to at least one second pin of the plurality of pins, entering a water detection mode when the first detection result indicates the presence of water, and detecting whether there is water in the connector based on resistance of the at least one second pin.

Abstract: The present disclosure relates to a magnetic resonance imaging (MRI) contrast agent containing a gadolinium complex, and more specifically, to a DO3A-tranexamic acid compound having a structure of a chemical formula 1, or an ester compound thereof, and gadolinium complexes thereof. The DO3A-tranexamic acid compound or the ester compound thereof may be used to prepare gadolinium complexes. The gadolinium complexes exhibit thermodynamic and kinetic stabilities, and show the relaxation rate equal to that of the clinical contrast agent which is currently commercially available. Therefore, the gadolinium complexes can be widely used as an MRI contrast agent.

Abstract: The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11?-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11?-HSD1 (11?-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11?-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

Abstract: The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11?-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11?-HSD1 (11?-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11?-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent including a gadolinium complex, more particularly to a DO3A-tranexamic acid or its ester compound, which is represented by the Chemical Formula 1. A DO3A-tranexamic acid or its ester compound may be prepared according to the present invention and a gadolinium complex may be prepared using the compound. An MRI contrast agent including the gadolinium complex prepared according to the present invention as an active ingredient has higher relaxivity as compared to the currently commercially available contrast agent. In addition, the MRI contrast agent according to the present invention has bifunctionality of liver-specific and blood-pool contrasting effect.

Abstract: The present invention relates to a paramagnetic polynuclear metal complex having enhanced self-relaxation rate and thermodynamic stability, and more particularly, to a synthetic method of a novel DTPA-bis-amide-histidine ligand and DTPA-bis-amide-aspartic acid ligand, a novel gadolinium complex ([Gd(L)H2O]) using the ligand, and a paramagnetic polynuclear metal complex using the gadolinium complex. The paramagnetic polynuclear metal complex is able to fix three or more metals (one gadolinium and two metal ions), thereby providing more excellent self-relaxation rate than the commercially available contrast agents. Thus, it can be widely applied to an MRI contrast agent because of meeting the high self-relaxation rate required as a contrast agent of magnetic resonance imaging (MRI).

Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent including a gadolinium complex, more particularly to a DO3A-tranexamic acid or its ester compound, which is represented by the Chemical Formula 1. A DO3A-tranexamic acid or its ester compound may be prepared according to the present invention and a gadolinium complex may be prepared using the compound. An MRI contrast agent including the gadolinium complex prepared according to the present invention as an active ingredient has higher relaxivity as compared to the currently commercially available contrast agent. In addition, the MRI contrast agent according to the present invention has bifunctionality of liver-specific and blood-pool contrasting effect.

Abstract: The present invention relates to a paramagnetic polynuclear metal complex having enhanced self-relaxation rate and thermodynamic stability, and more particularly, to a synthetic method of a novel DTPA-bis-amide-histidine ligand and DTPA-bis-amide-aspartic acid ligand, a novel gadolinium complex ([Gd(L)H2O]) using the ligand, and a paramagnetic polynuclear metal complex using the gadolinium complex. The paramagnetic polynuclear metal complex is able to fix three or more metals (one gadolinium and two metal ions), thereby providing more excellent self-relaxation rate than the commercially available contrast agents. Thus, it can be widely applied to an MRI contrast agent because of meeting the high self-relaxation rate required as a contrast agent of magnetic resonance imaging (MRI).

Abstract: A method for producing a titanium dioxide photocatalyst is provided. The method uses a sol-gel process wherein acid and base catalysts are added in two separate steps. According to the method, a titanium dioxide photocatalyst with increased mesoporosity can be produced without the use of any particular additive. Further, an anatase structure is formed upon drying and is maintained even after high-temperature calcination. Further provided is a titanium dioxide photocatalyst produced by the method. Further provided is a titanium dioxide photocatalyst doped with sulfur and zirconium, which is produced by using the method. The doped titanium dioxide photocatalyst exhibits catalytic activity even under visible light and excellent surface characteristics to achieve improved photocatalytic activity.

Abstract: The present invention relates to a method of forming air holes in a hollow fiber membrane module for water treatment. A main object of the present invention is to easily form air holes in the potting material injected into the module housing to prevent contamination of the hollow fiber membranes in the module housing.

Abstract: A method for producing a titanium dioxide photocatalyst is provided. The method uses a sol-gel process wherein acid and base catalysts are added in two separate steps. According to the method, a titanium dioxide photocatalyst with increased mesoporosity can be produced without the use of any particular additive. Further, an anatase structure is formed upon drying and is maintained even after high-temperature calcination. Further provided is a titanium dioxide photocatalyst produced by the method. Further provided is a titanium dioxide photocatalyst doped with sulfur and zirconium, which is produced by using the method. The doped titanium dioxide photocatalyst exhibits catalytic activity even under visible light and excellent surface characteristics to achieve improved photocatalytic activity.

Abstract: The present invention relates to emitting compounds for organic electroluminescent device, particularly to phenyl pyridine-iridium metal complex compounds represented by the following formula (1): wherein R1 to R8, A1 to A3, and Py are as defined in the specification. In addition, the present invention relates to an organic electroluminescent device comprising the above material which has high luminescence efficiency, enhanced operating life time, and high purity of red chromaticity.

Abstract: The present invention relates to a polyvinylidene difluoride hollow fiber membrane and a method of preparing the same, and more particularly, to an improved polyvinylidene difluoride hollow fiber membrane and a preparation method thereof, in which a spinning solution consisting of polyvinylidene fluoride, alcohol dendrimer and organic solvent is prepared, and then is subjected to solidification by a wet-phase transition process, cleaning and drying, in which alcohol dendrimer that is an organic material as a pore former is introduced, allowing uniform disperse of alcohol dendrimer in polyvinylidene difluoride to form pores, with each having a high dispersion ability and a uniform size, and in which an excellent adhesion durability is imparted, owing to the use of a single material of polyvinylidene difluoride, unlike the conventional hollow fiber membrane preparation method in which pores are formed using existing inorganic particles.

Abstract: The present invention relates to emitting compounds for organic electroluminescent device, particularly to porphines-platinum metal complex compounds represented by the following formula (1): wherein R1 and R2 are as defined in the specification. In addition, the present invention relates to an organic electroluminescent device comprising the above material which has high luminescence efficiency, enhanced operating life time, and high purity of red chromaticity.

Abstract: The present invention relates to luminescence materials for an organic electroluminescent device (OELD), and particularly to phenyl pyridine-iridium metal complex compounds of formula (1), and preparation method thereof. In addition, the present invention relates to an organic electroluminescent device using the luminescence materials according to the present invention, which can greatly enhance the efficiency of luminescence and increase the operating life time of the device: wherein R1, R2 and R3 each are the same as defined in the specification.

Abstract: The present invention relates to emitting compounds for organic electroluminescent device, particularly to phenyl pyridine-iridium metal complex compounds represented by the following formula (1): wherein R1 to R8, A1 to A3, and Py are as defined in the specification. In addition, the present invention relates to an organic electroluminescent device comprising the above material which has high luminescence efficiency, enhanced operating life time, and high purity of red chromaticity.